Mao X, Ma K, Wang Y, Long C, Tan X, Chen X, et al. Characterizing neurofibromin 1-altered breast cancer through genomic, functional, and clinical analyses. Virchows Arch. 2025. https://doi.org/10.1007/s00428-025-04218-y.
Ma K, Mao X, Zhuang H, Long C, Chen B. Independent effects of mental health disorders on breast cancer and their mediating factors: evidence from NHANES and two-step Mendelian randomization. Discov Oncol. 2025;16:1533.
Google Scholar
Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple negative breast cancer. BMJ. 2023;381:e071674.
Google Scholar
Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer – expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19:91–113.
Google Scholar
Fan M, Gao J, Zhou L, Xue W, Wang Y, Chen J, et al. Highly expressed SERCA2 triggers tumor cell autophagy and is a druggable vulnerability in triple-negative breast cancer. Acta Pharm Sin B. 2022;12:4407–23.
Google Scholar
Sonkin D, Thomas A, Teicher BA. Cancer treatments: past, present, and future. Cancer Genetics. 2024;286-287:18–24.
Google Scholar
Mao XD, Wei X, Xu T, Li TP, Liu KS. Research progress in breast cancer stem cells: characterization and future perspectives. Am J Cancer Res. 2022;12:3208–22.
Google Scholar
Denkert C, Liedtke C, Tutt A, von Minckwitz G. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017;389:2430–42.
Google Scholar
Saygin C, Matei D, Majeti R, Reizes O, Lathia JD. Targeting cancer stemness in the clinic: from hype to hope. Cell Stem Cell. 2019;24:25–40.
Google Scholar
Jia D, Li L, Andrew S, Allan D, Li X, Lee J, et al. An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells. Cell Death Dis. 2017;8:e2932.
Google Scholar
Sulaiman A, McGarry S, Lam KM, El-Sahli S, Chambers J, Kaczmarek S, et al. Co-inhibition of mTORC1, HDAC and ESR1alpha retards the growth of triple-negative breast cancer and suppresses cancer stem cells. Cell Death Dis. 2018;9:815.
Google Scholar
Sun Z, Zhao M, Wang W, Hong L, Wu Z, Luo G, et al. 5-ALA mediated photodynamic therapy with combined treatment improves anti-tumor efficacy of immunotherapy through boosting immunogenic cell death. Cancer Lett. 2023;554:216032.
Google Scholar
Wang Q, Yang T, Li S, Xu C, Wang C, Xiong Y, et al. Unimolecular self-assembled hemicyanine-oleic acid conjugate acts as a novel succinate dehydrogenase inhibitor to amplify photodynamic therapy and eliminate cancer stem cells. Research. 2023;6:0223.
Google Scholar
Wu S, Lu J, Zhu H, Wu F, Mo Y, Xie L, et al. A novel axis of circKIF4A-miR-637-STAT3 promotes brain metastasis in triple-negative breast cancer. Cancer Lett. 2024;581:216508.
Google Scholar
Huang X, Song C, Zhang J, Zhu L, Tang H. Circular RNAs in breast cancer diagnosis, treatment and prognosis. Oncol Res. 2023;32:241–9.
Google Scholar
Dai D, Zhang J, Mo Y, Song C, Liu L, Chen ZS, et al. CircPLK1 upregulates ETS1 to confer anthracycline resistance in triple-negative breast cancer. J Transl Int Med. 2025;13:267–80.
Google Scholar
Zhang Y, Li C, Liu X, Wang Y, Zhao R, Yang Y, et al. circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637. EBioMedicine. 2019;48:277–88.
Google Scholar
Liu Y, Zhai R, Hu S, Liu J. Circular RNA circ-RNF121 contributes to cisplatin (DDP) resistance of non-small-cell lung cancer cells by regulating the miR-646/SOX4 axis. Anticancer Drugs. 2022;33:e186–e197.
Google Scholar
Wang X, Chen T, Li C, Li W, Zhou X, Li Y, et al. CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR. J Hematol Oncol. 2022;15:122.
Google Scholar
Zhang Z, Chen WQ, Zhang SQ, Bai JX, Liu B, Yung KK, et al. Isoliquiritigenin inhibits pancreatic cancer progression through blockade of p38 MAPK-regulated autophagy. Phytomedicine. 2022;106:154406.
Google Scholar
Xiang S, Jian L, Zeng H, Wu H, Ge B, Zhang P, et al. Isoliquiritigenin suppresses the progression of malignant melanoma via targeting H2A.Z.1-E2F1 pathway. Biochem Pharmacol. 2023;218:115859.
Google Scholar
Peng F, Tang H, Liu P, Shen J, Guan X, Xie X, et al. Isoliquiritigenin modulates miR-374a/PTEN/Akt axis to suppress breast cancer tumorigenesis and metastasis. Sci Rep. 2017;7:9022.
Google Scholar
Peng F, Tang H, Du J, Chen J, Peng C. Isoliquiritigenin suppresses EMT-induced metastasis in triple-negative breast cancer through miR-200c/C-JUN/β-catenin. Am J Chin Med. 2021;49:505–23.
Google Scholar
Xie Y, Xie J, Huang G, Zhang J, Song C, Luo Y, et al. Isoliquiritigenin reduces brain metastasis by circNAV3-ST6GALNAC5-EGFR axis in triple-negative breast cancer. Cancer Lett. 2025;624:217734.
Google Scholar
Zhou Z, Han S, Liao J, Wang R, Yu X, Li M. Isoliquiritigenin inhibits oral squamous cell carcinoma and overcomes chemoresistance by destruction of survivin. Am J Chinese Med. 2023;51:2221–41.
Google Scholar
Liu A, Jiang B, Song C, Zhong Q, Mo Y, Yang R, et al. Isoliquiritigenin inhibits circ0030018 to suppress glioma tumorigenesis via the miR-1236/HER2 signaling pathway. MedComm. 2023;4:e282.
Google Scholar
Chen B, Lai J, Dai D, Chen R, Liao N, Gao G, et al. PARPBP is a prognostic marker and confers anthracycline resistance to breast cancer. Ther Adv Med Oncol. 2020;12:1758835920974212.
Google Scholar
Chen B, Wei W, Huang X, Xie X, Kong Y, Dai D, et al. circEPSTI1 as a prognostic marker and mediator of triple-negative breast cancer progression. Theranostics. 2018;8:4003–15.
Google Scholar
Yin Y, Yan Y, Fan B, Huang W, Zhang J, Hu HY, et al. Novel combination therapy for triple-negative breast cancer based on an intelligent hollow carbon sphere. Research (Wash D C). 2023;6:0098.
Google Scholar
Xie J, Ye F, Deng X, Tang Y, Liang JY, Huang X, et al. Circular RNA: a promising new star of vaccine. J Transl Int Med. 2023;11:372–81.
Google Scholar
Chen DL, Sheng H, Zhang DS, Jin Y, Zhao BT, Chen N, et al. The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p. Mol Cancer. 2021;20:166.
Google Scholar
Zeng Y, Du W, Huang Z, Wu S, Ou X, Zhang J, et al. Hsa_circ_0060467 promotes breast cancer liver metastasis by complexing with eIF4A3 and sponging miR-1205. Cell Death Discov. 2023;9:153.
Google Scholar
Liu J, Wang H, Xiao S, Zhang S, Qi Y, Wang M. Circ_0000231 promotes paclitaxel resistance in ovarian cancer by regulating miR-140/RAP1B. Am J Cancer Res. 2023;13:872–85.
Google Scholar
Liu S, Sun Y, Hou Y, Yang L, Wan X, Qin Y, et al. A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties. J Hematol Oncol. 2021;14:178.
Google Scholar
Zhou M, Hou Y, Yang G, Zhang H, Tu G, Du YE, et al. LncRNA-Hh strengthen cancer stem cells generation in twist-positive breast cancer via activation of hedgehog signaling pathway. Stem Cells. 2016;34:55–66.
Google Scholar
Gu Y, Wang Y, He L, Zhang J, Zhu X, Liu N, et al. Circular RNA circIPO11 drives self-renewal of liver cancer initiating cells via Hedgehog signaling. Mol Cancer. 2021;20:132.
Google Scholar
Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17:559–72.
Google Scholar
Yu X, Yuan Z, Yang Z, Chen D, Kim T, Cui Y, et al. The novel long noncoding RNA u50535 promotes colorectal cancer growth and metastasis by regulating CCL20. Cell Death Dis. 2018;9:751.
Google Scholar
Cheng XS, Li YF, Tan J, Sun B, Xiao YC, Fang XB, et al. CCL20 and CXCL8 synergize to promote progression and poor survival outcome in patients with colorectal cancer by collaborative induction of the epithelial-mesenchymal transition. Cancer Lett. 2014;348:77–87.
Google Scholar
Jin P, Shin SH, Chun YS, Shin HW, Shin YJ, Lee Y, et al. Astrocyte-derived CCL20 reinforces HIF-1-mediated hypoxic responses in glioblastoma by stimulating the CCR6-NF-kappaB signaling pathway. Oncogene. 2018;37:3070–87.
Google Scholar
Lee SK, Park KK, Kim HJ, Park J, Son SH, Kim KR, et al. Human antigen R-regulated CCL20 contributes to osteolytic breast cancer bone metastasis. Sci Rep. 2017;7:9610.
Google Scholar
Wang D, Yang L, Yu W, Wu Q, Lian J, Li F, et al. Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-kappaB signaling. J Immunother Cancer. 2019;7:215.
Google Scholar
Chen W, Qin Y, Wang D, Zhou L, Liu Y, Chen S, et al. CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer. PLoS Biol. 2018;16:e2005869.
Google Scholar
Meitei HT, Jadhav N, Lal G. CCR6-CCL20 axis as a therapeutic target for autoimmune diseases. Autoimmunity reviews. 2021;20:102846.
Google Scholar
Skovdahl HK, Damås JK, Granlund AVB, Østvik AE, Doseth B, Bruland T, et al. C-C Motif Ligand 20 (CCL20) and C-C motif chemokine receptor 6 (CCR6) in human peripheral blood mononuclear cells: dysregulated in ulcerative colitis and a potential role for CCL20 in IL-1β release. Int J Mol Sci. 2018;19:3257.
Google Scholar
Wang X, Zhang H, Chen X, Wu C, Ding K, Sun G, et al. Overcoming tumor microenvironment obstacles: current approaches for boosting nanodrug delivery. Acta Biomater. 2023;166:42–68.
Google Scholar
Muscella A, Vetrugno C, Marsigliante S. CCL20 promotes migration and invasiveness of human cancerous breast epithelial cells in primary culture. Mol Carcinogenesis. 2017;56:2461–73.
Google Scholar
Ouyang J, Hu S, Zhu Q, Li C, Kang T, Xie W, et al. RANKL/RANK signaling recruits Tregs via the CCL20-CCR6 pathway and promotes stemness and metastasis in colorectal cancer. Cell Death Dis. 2024;15:437.
Google Scholar
Wang D, Yang L, Yu W, Wu Q, Lian J, Li F, et al. Colorectal cancer cell-derived CCL20 recruits regulatory T cells to promote chemoresistance via FOXO1/CEBPB/NF-κB signaling. J Immunother Cancer. 2019;7:215.
Google Scholar
Famta P, Shah S, Jain N, Kumar KC, Bagasariya D, Khatri DK, et al. Tumor-promoting aftermath post-chemotherapy: A focus on breast cancer. Life Sci. 2022;310:121125.
Google Scholar
He HN, Wang X, Zheng XL, Sun H, Shi XW, Zhong YJ, et al. Concurrent blockade of the NF-kappaB and Akt pathways potently sensitizes cancer cells to chemotherapeutic-induced cytotoxicity. Cancer Lett. 2010;295:38–43.
Google Scholar
Shi Z, Cao X, Ma Y, Li K, Wang X, Lin J, et al. RNA methyltransferase METTL16: From molecular mechanisms to therapeutic prospects in cancers. Cancer Lett. 2025;624:217698.
Google Scholar
Yin Z, Zhou Y, Zhu X, Goettl RA, Wang C, Weiss HL, et al. Cancer-associated fibroblast secreted DKK1 promotes the immunosuppressive tumor microenvironment and colorectal cancer resistance to chemotherapy. Cancer Lett. 2025;634:218060.
Google Scholar
Cuadrado A, Corrado N, Perdiguero E, Lafarga V, Munoz-Canoves P, Nebreda AR. Essential role of p18Hamlet/SRCAP-mediated histone H2A.Z chromatin incorporation in muscle differentiation. EMBO J. 2010;29:2014–25.
Google Scholar
Ye B, Liu B, Yang L, Zhu X, Zhang D, Wu W, et al. LncKdm2b controls self-renewal of embryonic stem cells via activating expression of transcription factor Zbtb3. EMBO J. 2018; 37.
Monroy MA, Schott NM, Cox L, Chen JD, Ruh M, Chrivia JC. SNF2-related CBP activator protein (SRCAP) functions as a coactivator of steroid receptor-mediated transcription through synergistic interactions with CARM-1 and GRIP-1. Mol Endocrinol. 2003;17:2519–28.
Google Scholar
Ghosh AK, Majumder M, Steele R, Yaciuk P, Chrivia J, Ray R, et al. Hepatitis C virus NS5A protein modulates transcription through a novel cellular transcription factor SRCAP. J Biol Chem. 2000;275:7184–8.
Google Scholar
Cao W, Liu X, Su W, Liang H, Tang H, Zhang W, et al. LINC00665 sponges miR-641 to promote the progression of breast cancer by targeting the SNF2-related CREBBP activator protein (SRCAP). Bioengineered. 2022;13:4573–86.
Google Scholar
Slupianek A, Yerrum S, Safadi FF, Monroy MA. The chromatin remodeling factor SRCAP modulates expression of prostate specific antigen and cellular proliferation in prostate cancer cells. J Cell Physiol. 2010;224:369–75.
Google Scholar
Dong S, Han J, Chen H, Liu T, Huen MSY, Yang Y, et al. The human SRCAP chromatin remodeling complex promotes DNA-end resection. Curr Biol. 2014;24:2097–110.
Google Scholar
Liu X, Zhao S, Xu X, Liu X, Zhang Y, Zhao S, et al. Circ(-)0008536 inhibits doxorubicin resistance in triple-negative breast cancer via the miR-382-5p/GGNBP2 axis. Transl Oncol. 2025;61:102526.
Google Scholar
Chen J, Li Y, Zheng Q, Bao C, He J, Chen B, et al. Circular RNA profile identifies circPVT1 as a proliferative factor and prognostic marker in gastric cancer. Cancer Lett. 2017;388:208–19.
Google Scholar
